At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
ADX-629 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19
In Brief
A Phase 2 clinical trial evaluating ADX-629 and Placebo for Covid19. Completed, enrolled 11 participants across 1 site.
Detailed Summary
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMar 2021
First PostedApr 2021
Primary CompletionOct 2021
TodayJul 2026
First PostedApr 19, 2021
Enrollment StartMar 31, 2021
Primary CompletionOct 15, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.2 years ago
Interventions
ADX-629drug
ADX-629 administered orally twice daily (BID) for up to 28 days.
Placebodrug
Placebo administered orally BID for up to 28 days.